Highlights Kancera AB

Equities

KAN

SE0015658570

Delayed Nasdaq Stockholm Other stock markets 10:07:03 2024-06-26 EDT			5-day change	1st Jan Change
1.642 ^SEK	+2.37%		-1.91%	-63.87%

05-17	Kancera AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-16	Kancera AB Provides Operational Update Regarding the Kandova Study and Reports Increased Patient Recruitment	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Kancera AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-17	CI
Kancera AB Provides Operational Update Regarding the Kandova Study and Reports Increased Patient Recruitment	05-16	CI
Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	05-03	CI
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Kancera AB Signs A License Agreement with the University of Newcastle	02-23	CI
Kancera AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22	CI
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study	02-06	CI
Kancera AB Reports Positive Top Line Results from the FRACTAL Study	12-20	CI
Kancera AB Provides Operational Update Regarding Fractalkine Block Blockers KAN567 and KAND145	11-17	CI
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-17	CI
Kancera AB Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145	23-10-23	CI
Kancera AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Kancera AB Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease	23-07-24	CI
Kancera AB Reports Dosing of First Patient in the KANDOVA Study	23-06-19	CI
Kancera AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-19	CI
Kancera AB Submits Application to Conduct First-In-Human Study of Kand145	23-04-24	CI
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-21	CI
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-21	CI
Kancera AB Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer	22-12-22	CI
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kancera AB

Equities

KAN

SE0015658570

Highlights

Filters